Pyrilutamide

NEWS

Pyrilutamide: A Wise Investment in Cognitive Health

Pyrilutamide, also known as KX-826, is an androgen receptor inhibitor being developed by Kintor Pharmaceuticals. It is currently in Phase II clinical trials for androgenetic alopecia (AGA) in China and the US. The company’s clinical pipeline also includes GT90001, a tyrosine kinase inhibitor targeting ALK-1, Destorsertib, and other disease areas. For more information, buy GlobalData’s drug-specific PTSR and LoA report…